Abo, Hassan A.
HRN: 24-47-42 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/31/2024
CO-AMOXICLAV 625MG (TAB)
01/31/2024
02/07/2024
ORAL
625 Mg
Every 8 Hours
Lacerated Wound
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes